These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 659585)

  • 1. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.
    Fine SA; Frohman LA
    J Clin Invest; 1978 Apr; 61(4):973-80. PubMed ID: 659585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrity of central dopaminergic system in women with postpartum hyperprolactinemia.
    Rao R; Scommegna A; Frohman LA
    Am J Obstet Gynecol; 1982 Aug; 143(8):883-7. PubMed ID: 7102764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperprolactinemia in hepatic encephalopathy may result from impaired central dopaminergic neurotransmission.
    Corenblum B; Shaffer EA
    Horm Metab Res; 1989 Dec; 21(12):675-7. PubMed ID: 2559014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catecholamines and pituitary function. 2. Prolactin response to different dopamine doses in normal cycling women and patients with prolactin-secreting pituitary tumors, both before and after endogenous catecholamine synthesis inhibition.
    Nicoletti I; Filipponi P; Fedeli L; Gregorini G; Ambrosi F; Sfrappini M; Santeusanio F; Brunetti P
    Horm Metab Res; 1984 Dec; 16(12):658-62. PubMed ID: 6441763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of 6-pyruvoyl-tetrahydropterin synthase deficiency demonstrates a more significant correlation of L-Dopa dosage with serum prolactin levels than CSF homovanillic acid levels.
    Ogawa A; Kanazawa M; Takayanagi M; Kitani Y; Shintaku H; Kohno Y
    Brain Dev; 2008 Jan; 30(1):82-5. PubMed ID: 17590551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical cure of prolactinoma reverses abnormal prolactin repsonse to carbidopa/L-dopa.
    Molitch ME; Goodman RH; Post KD; Biller BJ; Moses AC; King LW; Feldman ZT; Reichlin S
    J Clin Endocrinol Metab; 1982 Dec; 55(6):1118-23. PubMed ID: 7130339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbidopa inhibits the growth hormone- and prolactin-suppressive effect of L-dopa in acromegalic patients.
    Camanni F; Picotti GB; Massara F; Molinatti GM; Mantegazza P; Müller EE
    J Clin Endocrinol Metab; 1978 Sep; 47(3):647-52. PubMed ID: 263317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of hypothalamic dopaminergic function in patients with pituitary prolactinoma.
    Xia P; Shi YF
    Proc Chin Acad Med Sci Peking Union Med Coll; 1989; 4(3):121-5. PubMed ID: 2594732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
    Ishibashi M; Yamaji T
    J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of CNS dopamine augmentation on stimulated prolactin secretion.
    Woolf PD; Leebaw WJ; Lee LA
    J Clin Endocrinol Metab; 1977 Oct; 45(4):857-60. PubMed ID: 410827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbidopa plus L-dopa pretreatment inhibits the prolactin (PRL) response to thyrotropin-releasing hormone and thus cannot distinguish central from pituitary sites of prolactin stimulation.
    Carlson HE
    J Clin Endocrinol Metab; 1986 Jul; 63(1):249-51. PubMed ID: 3086358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro effect of dopamine and L-dopa on prolactin and growth hormone release from human pituitary adenomas.
    Peillon F; Cesselin F; Bression D; Zygelman N; Brandi AM; Nousbaum A; Mauborgne A
    J Clin Endocrinol Metab; 1979 Nov; 49(5):737-41. PubMed ID: 489713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients.
    Lissoni P; Malugani F; Casu M; Bukovec R; Egardi R; Bordin V; Fumagalli E; Mengo S; Gardani G
    Neuro Endocrinol Lett; 2002 Feb; 23(1):61-3. PubMed ID: 11880864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.
    Rose S; Jenner P; Marsden CD
    Mov Disord; 1988; 3(2):117-25. PubMed ID: 3221899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional characterization of hypothalamic hyperprolactinemia.
    Ferrari C; Rampini P; Benco R; Caldara R; Scarduelli C; Crosignani PG
    J Clin Endocrinol Metab; 1982 Nov; 55(5):897-901. PubMed ID: 6811605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Various aspects of dopaminergic function in patients with prolactin-secreting hypophyseal adenoma].
    De Leo V; Franchi F; Danero S; Ricci MG; La Marca S; Urbani TM; Pieroni ML; D'Antona N; Genazzani AR
    Boll Soc Ital Biol Sper; 1983 Dec; 59(12):1883-9. PubMed ID: 6671047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic mechanisms regulating prolactin secretion in patients with prolactin-secreting pituitary adenoma. Long-term studies after selective transsphenoidal surgery.
    Barbarino A; De Marinis L; Anile C; Menini E; Merlini G; Maira G
    Metabolism; 1982 Nov; 31(11):1100-4. PubMed ID: 6813636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hypothalamic dopamine (DA) on salsolinol (SAL)-induced prolactin (PRL) secretion in male goats.
    Jin J; Hara S; Sawai K; Fülöp F; Nagy GM; Hashizume T
    Anim Sci J; 2014 Apr; 85(4):461-7. PubMed ID: 24329779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease.
    Bell RD; Carruth A; Rosenberg RN; Boyar RM
    J Clin Endocrinol Metab; 1978 Oct; 47(4):807-11. PubMed ID: 45469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic administration does not alter the accumulation of L-dopa into muscle.
    Rose S; Jenner P; Marsden CD
    Mov Disord; 1994 Mar; 9(2):167-72. PubMed ID: 8196677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.